{"transactions":[{"id":871065,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2026-03-03T18:09:03.000Z","date":"2026-02-27","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service with the Issuer at each vesting date."}],"balance_after":175000,"derivative":{"exercise_price":11.52,"expiration_date":"2036-02-27","underlying":"Common Shares","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001898799-26-000004","document":"wk-form4_1772579341.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000189879926000004/wk-form4_1772579341.xml","form_type":"4"}},{"id":945224,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Share Unit Award","published_at":"2026-01-07T21:33:22.000Z","date":"2026-01-05","kind":"exercise","planned":false,"acquired":false,"shares":4250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted share unit represents the contingent right to receive one common share of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each restricted share unit represents the contingent right to receive one common share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The reporting person was granted 17,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Not applicable."}],"balance_after":8500,"derivative":{"underlying":"Common Shares","underlying_shares":4250},"source":{"system":"sec-edgar","filing":"0001898799-26-000002","document":"wk-form4_1767839598.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000189879926000002/wk-form4_1767839598.xml","form_type":"4"}},{"id":945223,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2026-01-07T21:33:22.000Z","date":"2026-01-05","kind":"tax_withholding","planned":false,"acquired":false,"shares":2594,"price":9.93,"value":25758.42,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This balance includes 544 shares that were acquired through the Biohaven Employee Share Purchase Plan on May 31, 2025."}],"balance_after":195652,"source":{"system":"sec-edgar","filing":"0001898799-26-000002","document":"wk-form4_1767839598.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000189879926000002/wk-form4_1767839598.xml","form_type":"4"}},{"id":945222,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2026-01-07T21:33:22.000Z","date":"2026-01-05","kind":"exercise","planned":false,"acquired":true,"shares":4250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This balance includes 544 shares that were acquired through the Biohaven Employee Share Purchase Plan on May 31, 2025."}],"balance_after":198246,"source":{"system":"sec-edgar","filing":"0001898799-26-000002","document":"wk-form4_1767839598.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000189879926000002/wk-form4_1767839598.xml","form_type":"4"}},{"id":1309091,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Share Unit Award","published_at":"2025-01-07T20:49:17.000Z","date":"2025-01-05","kind":"exercise","planned":false,"acquired":false,"shares":4250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted share unit represents the contingent right to receive one common share of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each restricted share unit represents the contingent right to receive one common share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The reporting person was granted 17,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Not applicable."}],"balance_after":12750,"derivative":{"underlying":"Common Shares","underlying_shares":4250},"source":{"system":"sec-edgar","filing":"0001935979-25-000003","document":"wk-form4_1736300950.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000193597925000003/wk-form4_1736300950.xml","form_type":"4"}},{"id":1309090,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Share Unit Award","published_at":"2025-01-07T20:49:17.000Z","date":"2025-01-05","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted share unit represents the contingent right to receive one common share of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each restricted share unit represents the contingent right to receive one common share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The reporting person was granted 17,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Not applicable."}],"balance_after":17000,"derivative":{"underlying":"Common Shares","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001935979-25-000003","document":"wk-form4_1736300950.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000193597925000003/wk-form4_1736300950.xml","form_type":"4"}},{"id":1309089,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2025-01-07T20:49:17.000Z","date":"2025-01-05","kind":"grant","planned":false,"acquired":true,"shares":104000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option vest in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service with the Issuer at each vesting date."}],"balance_after":104000,"derivative":{"exercise_price":38.64,"expiration_date":"2035-01-05","underlying":"Common Shares","underlying_shares":104000},"source":{"system":"sec-edgar","filing":"0001935979-25-000003","document":"wk-form4_1736300950.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000193597925000003/wk-form4_1736300950.xml","form_type":"4"}},{"id":1309088,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2025-01-07T20:49:17.000Z","date":"2025-01-05","kind":"tax_withholding","planned":false,"acquired":false,"shares":2561,"price":38.64,"value":98957.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This balance includes 305 shares that were acquired through the Biohaven Employee Share Purchase Plan (the \"ESPP\") on May 31, 2023, 1,336 shares acquired through the ESPP on November 30, 2023, and 742 shares acquired through the ESPP on May 31, 2024."}],"balance_after":193452,"source":{"system":"sec-edgar","filing":"0001935979-25-000003","document":"wk-form4_1736300950.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000193597925000003/wk-form4_1736300950.xml","form_type":"4"}},{"id":1309087,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2025-01-07T20:49:17.000Z","date":"2025-01-05","kind":"exercise","planned":false,"acquired":true,"shares":4250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This balance includes 305 shares that were acquired through the Biohaven Employee Share Purchase Plan (the \"ESPP\") on May 31, 2023, 1,336 shares acquired through the ESPP on November 30, 2023, and 742 shares acquired through the ESPP on May 31, 2024."}],"balance_after":196013,"source":{"system":"sec-edgar","filing":"0001935979-25-000003","document":"wk-form4_1736300950.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000193597925000003/wk-form4_1736300950.xml","form_type":"4"}},{"id":1689250,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2024-01-04T20:07:33.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":96250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in four equal installments on January 2, 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service with the Issuer at each vesting date."}],"balance_after":96250,"derivative":{"exercise_price":41.93,"expiration_date":"2034-01-02","underlying":"Common Shares","underlying_shares":96250},"source":{"system":"sec-edgar","filing":"0001562180-24-000284","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000156218024000284/primarydocument.xml","form_type":"4"}},{"id":1749061,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2023-11-06T20:34:31.000Z","date":"2023-11-02","kind":"grant","planned":false,"acquired":true,"shares":78750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in four equal installments on November 2, 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service with the Issuer at each vesting date."}],"balance_after":78750,"derivative":{"exercise_price":29.49,"expiration_date":"2033-11-02","underlying":"Common Shares","underlying_shares":78750},"source":{"system":"sec-edgar","filing":"0001562180-23-007580","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000156218023007580/primarydocument.xml","form_type":"4"}},{"id":1763940,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2023-10-06T07:38:01.000Z","date":"2023-10-05","kind":"purchase","planned":false,"acquired":true,"shares":22727,"price":22,"value":499994.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents common shares acquired in an underwritten public offering."}],"balance_after":189380,"source":{"system":"sec-edgar","filing":"0001562180-23-007229","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000156218023007229/primarydocument.xml","form_type":"4"}},{"id":2131915,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2022-10-26T18:21:44.000Z","date":"2022-10-25","kind":"purchase","acquired":true,"shares":142857,"price":10.5,"value":1499998.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents common shares acquired in an underwritten public offering."}],"balance_after":166653,"source":{"system":"sec-edgar","filing":"0001562180-22-007333","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000156218022007333/primarydocument.xml","form_type":"4"}},{"id":2142842,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-10-05T17:36:19.000Z","date":"2022-10-03","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying this option vest in four equal installments on October 4, 2022, 2023, 2024, and 2025, subject to the reporting person's continuous service with the Issuer at each vesting date."}],"balance_after":300000,"derivative":{"exercise_price":7,"expiration_date":"2032-10-04","underlying":"Common Shares","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001562180-22-007076","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000156218022007076/primarydocument.xml","form_type":"4"}},{"id":2142841,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-10-05T17:36:19.000Z","date":"2022-10-03","kind":"exercise","acquired":false,"shares":11450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement."}],"balance_after":0,"derivative":{"exercise_price":6.37,"expiration_date":"2032-01-07","underlying":"Common Shares","underlying_shares":11450},"source":{"system":"sec-edgar","filing":"0001562180-22-007076","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000156218022007076/primarydocument.xml","form_type":"4"}},{"id":2142840,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-10-05T17:36:19.000Z","date":"2022-10-03","kind":"exercise","acquired":false,"shares":1550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement."}],"balance_after":0,"derivative":{"exercise_price":6.37,"expiration_date":"2032-01-07","underlying":"Common Shares","underlying_shares":1550},"source":{"system":"sec-edgar","filing":"0001562180-22-007076","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000156218022007076/primarydocument.xml","form_type":"4"}},{"id":2142839,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-10-05T17:36:19.000Z","date":"2022-10-03","kind":"other","acquired":true,"shares":11450,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement."},{"field":"shares","element":"transactionShares","label":"F4","text":"Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement."}],"balance_after":11450,"derivative":{"exercise_price":6.37,"expiration_date":"2032-01-07","underlying":"Common Shares","underlying_shares":11450},"source":{"system":"sec-edgar","filing":"0001562180-22-007076","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000156218022007076/primarydocument.xml","form_type":"4"}},{"id":2142838,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-10-05T17:36:19.000Z","date":"2022-10-03","kind":"other","acquired":true,"shares":1550,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement."},{"field":"shares","element":"transactionShares","label":"F4","text":"Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement."}],"balance_after":1550,"derivative":{"exercise_price":6.37,"expiration_date":"2032-01-07","underlying":"Common Shares","underlying_shares":1550},"source":{"system":"sec-edgar","filing":"0001562180-22-007076","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000156218022007076/primarydocument.xml","form_type":"4"}},{"id":2142837,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2022-10-05T17:36:19.000Z","date":"2022-10-03","kind":"tax_withholding","acquired":false,"shares":11042,"price":7.5,"value":82815.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These shares were withheld by the Issuer in connection with share settlement to cover the cost of the stock options."}],"balance_after":23796,"source":{"system":"sec-edgar","filing":"0001562180-22-007076","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000156218022007076/primarydocument.xml","form_type":"4"}},{"id":2142836,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2022-10-05T17:36:19.000Z","date":"2022-10-03","kind":"exercise","acquired":true,"shares":11450,"price":6.37,"value":72936.5,"ownership":{"direct":true},"balance_after":34838,"source":{"system":"sec-edgar","filing":"0001562180-22-007076","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000156218022007076/primarydocument.xml","form_type":"4"}},{"id":2142835,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2022-10-05T17:36:19.000Z","date":"2022-10-03","kind":"exercise","acquired":true,"shares":1550,"price":6.37,"value":9873.5,"ownership":{"direct":true},"balance_after":23388,"source":{"system":"sec-edgar","filing":"0001562180-22-007076","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000156218022007076/primarydocument.xml","form_type":"4"}},{"id":2142834,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2022-10-05T17:36:19.000Z","date":"2022-10-03","kind":"other","acquired":true,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Effective as of the Distribution, each outstanding restricted share unit of RemainCo was adjusted so that such restricted share unit became a restricted share unit in respect of Common Shares (each, an \"Issuer RSU\") and a restricted share unit in respect of RemainCo common shares. At the effective time of the merger of a wholly owned subsidiary of Pfizer (\"Merger Sub\") with and into RemainCo pursuant to the Agreement and Plan of Merger, dated as of May 9, 2022, by and among RemainCo, Pfizer and Merger Sub, the Issuer RSUs accelerated and vested in full and were subsequently settled in Common Shares. As a result, the Reporting Person acquired restricted share units in respect of Common Shares in an amount determined in accordance with the Separation Agreement."}],"balance_after":21838,"source":{"system":"sec-edgar","filing":"0001562180-22-007076","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000156218022007076/primarydocument.xml","form_type":"4"}},{"id":2142833,"issuer":{"id":4379,"kind":"organization","name":"Biohaven Ltd.","symbol":"BHVN"},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2022-10-05T17:36:19.000Z","date":"2022-10-03","kind":"other","acquired":true,"shares":3088,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents common shares of the Issuer (\"Common Shares\") acquired by the Reporting Person in a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. (\"RemainCo\") to holders of its common shares (the \"Distribution\") pursuant to the Separation and Distribution Agreement (the \"Separation Agreement\"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. (\"Pfizer\")."}],"balance_after":3088,"source":{"system":"sec-edgar","filing":"0001562180-22-007076","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000156218022007076/primarydocument.xml","form_type":"4"}},{"id":2148009,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-10-03T20:28:30.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":22900,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"shares","element":"transactionShares","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":125.69,"expiration_date":"2032-01-07","underlying":"Common Shares","underlying_shares":22900},"source":{"system":"sec-edgar","filing":"0001562180-22-006959","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000156218022006959/primarydocument.xml","form_type":"4"}},{"id":2148008,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-10-03T20:28:30.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":3100,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"shares","element":"transactionShares","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a \"Post-Spin Issuer Option\"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":125.69,"expiration_date":"2032-01-07","underlying":"Common Shares","underlying_shares":3100},"source":{"system":"sec-edgar","filing":"0001562180-22-006959","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000156218022006959/primarydocument.xml","form_type":"4"}},{"id":2148007,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Share Unit Award","published_at":"2022-10-03T20:28:30.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":37500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"shares","element":"transactionShares","label":"F3","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"In connection with the distribution (\"Distribution\") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. (\"SpinCo\"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a \"Post-Spin Issuer RSU\"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001562180-22-006959","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000156218022006959/primarydocument.xml","form_type":"4"}},{"id":2148006,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2022-10-03T20:28:30.000Z","date":"2022-10-03","kind":"disposition_to_issuer","acquired":false,"shares":6177,"price":148.5,"value":917284.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Pfizer\") and a wholly owned subsidiary of Pfizer (\"Merger Sub\"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In the Merger, each common share of the Issuer (each, a \"Common Share\") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-22-006959","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000156218022006959/primarydocument.xml","form_type":"4"}},{"id":2440684,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-01-07T21:19:03.000Z","date":"2022-01-07","kind":"grant","acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in four equal installments on January 7, 2022, 2023, 2024 and 2025, subject to the reporting person's continuous service with the Issuer at each vesting date."}],"balance_after":26000,"derivative":{"exercise_price":128.87,"expiration_date":"2032-01-07","underlying":"Common Shares","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001562180-22-000358","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000156218022000358/primarydocument.xml","form_type":"4"}},{"id":2451700,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Share Unit Award","published_at":"2022-01-04T21:30:58.000Z","date":"2021-12-31","kind":"exercise","acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents the contingent right to receive one common share of the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents the contingent right to receive one common share of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted 50,000 restricted share units on December 8, 2021. 12,500 of the restricted share units vested on December 8, 2021 and were subject to deferred settlement. The remainder vest in three equal installments on December 8, 2022, 2023 and 2024 subject to the reporting person's continued service with the issuer at each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Not applicable."}],"balance_after":37500,"derivative":{"underlying":"Common Shares","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001562180-22-000183","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000156218022000183/primarydocument.xml","form_type":"4"}},{"id":2451699,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2022-01-04T21:30:58.000Z","date":"2021-12-31","kind":"tax_withholding","acquired":false,"shares":6323,"price":137.81,"value":871372.63,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"No shares were sold - these shares were withheld by the issuer in connection with mandatory share settlement to satisfy tax withholding requirements in connection with the vesting of restricted share units."}],"balance_after":6177,"source":{"system":"sec-edgar","filing":"0001562180-22-000183","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000156218022000183/primarydocument.xml","form_type":"4"}},{"id":2451698,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2022-01-04T21:30:58.000Z","date":"2021-12-31","kind":"exercise","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12500,"source":{"system":"sec-edgar","filing":"0001562180-22-000183","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000156218022000183/primarydocument.xml","form_type":"4"}},{"id":2474267,"issuer":{"id":123269,"kind":"organization","name":"Biohaven Pharmaceutical Holding Co Ltd."},"owners":[{"id":63643,"kind":"person","name":"Buten Matthew","position":1,"cik":"0001898799","reported_name":"Buten Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Officer"}}],"security":"Restricted Share Unit Award","published_at":"2021-12-14T20:52:43.000Z","date":"2021-12-08","kind":"grant","acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted share unit represents the contingent right to receive one common share of the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted share unit represents the contingent right to receive one common share of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reporting person was granted 50,000 restricted share units on December 8, 2021. 12,500 of the restricted share units vested on December 8, 2021 and are subject to deferred settlement. The remainder vest in three equal installments on December 8, 2022, 2023 and 2024 subject to the reporting person's continued service with the issuer at each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Not applicable."}],"balance_after":50000,"derivative":{"underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001562180-21-007699","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1898799/000156218021007699/primarydocument.xml","form_type":"4"}}]}